Quick Takeaways
- Sands Capital Life Sciences Pulse Fund II, L.P. filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT).
- Disclosed ownership: 11%.
- Date of event: 31 Dec 2025.
Sands Capital Life Sciences Pulse Fund II, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT)
- Filing Manager
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Reporting Manager
- Sands Capital Life Sciences Pulse Fund II, L.P.
- Symbol
- IKT
- Shares outstanding
- 120,545,972 shares
- Disclosed Ownership
- 13,018,965 shares
- Ownership
- 11%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 11:30:46 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 13 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Sands Capital Life Sciences Pulse Fund II, L.P. disclosed 11% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value per share (IKT) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 13 Aug 2025.
- Current filing was accepted on 13 Feb 2026, 11:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 11% | 13,018,965 | 13,018,965 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P. | ||
| Sands Capital Alternatives, LLC | 11% | 13,018,965 | 13,018,965 | /s/ Jonathan Goodman | Jonathan Goodman, General Counsel | ||
| SANDS FRANK M. | 11% | 13,018,965 | 13,018,965 | /s/ Frank M. Sands | Frank M. Sands |